Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.
Anti-HIV group I introns and uses thereof in treating HIV infections
Patent
Description
Attribute Name | Values |
---|---|
Title |
|
Patent Number |
|
USPTO Link | |
Inventor |
|
Inventor From Local Institution |
|
Other Application |
|
Prior Publication Date |
|
Prior Publication Number |
|
Claims |
|
Cooperative Patent Classification codes |
|
International Patent Classification codes |
|
Language |
|
Date Issued |
|
Publisher |
|
Assignee |
|
Record Visibility | Public |
Content License |
|
Departments and Units | |
Member of |
Collections Featuring this Patent |
---|
Notre Dame Patents |
Files
Thumbnail | File Name | Description | Size | Type | File Access | Actions |
---|---|---|---|---|---|---|
|
9,707,257 OCR.pdf | 1.17 MB | application/pdf | Public |
1 entry found